CA3083857A1 - Modified norovirus vp1 proteins and vlps comprising modified norovirus vp1 proteins - Google Patents

Modified norovirus vp1 proteins and vlps comprising modified norovirus vp1 proteins Download PDF

Info

Publication number
CA3083857A1
CA3083857A1 CA3083857A CA3083857A CA3083857A1 CA 3083857 A1 CA3083857 A1 CA 3083857A1 CA 3083857 A CA3083857 A CA 3083857A CA 3083857 A CA3083857 A CA 3083857A CA 3083857 A1 CA3083857 A1 CA 3083857A1
Authority
CA
Canada
Prior art keywords
norovirus
gii
protein
seq
plant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3083857A
Other languages
English (en)
French (fr)
Inventor
Pierre-Olivier Lavoie
Marc-Andre D'aoust
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medicago Inc
Original Assignee
Medicago Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medicago Inc filed Critical Medicago Inc
Publication of CA3083857A1 publication Critical patent/CA3083857A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
    • C12N15/8258—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon for the production of oral vaccines (antigens) or immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/03—Herpetoviridae, e.g. pseudorabies virus
    • C07K14/05—Epstein-Barr virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/16011—Caliciviridae
    • C12N2770/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/16011—Caliciviridae
    • C12N2770/16023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/16011—Caliciviridae
    • C12N2770/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
CA3083857A 2017-11-30 2018-11-30 Modified norovirus vp1 proteins and vlps comprising modified norovirus vp1 proteins Pending CA3083857A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762593006P 2017-11-30 2017-11-30
US62/593,006 2017-11-30
US201862712744P 2018-07-31 2018-07-31
US62/712,744 2018-07-31
PCT/CA2018/051530 WO2019104439A1 (en) 2017-11-30 2018-11-30 Modified norovirus vp1 proteins and vlps comprising modified norovirus vp1 proteins

Publications (1)

Publication Number Publication Date
CA3083857A1 true CA3083857A1 (en) 2019-06-06

Family

ID=66663733

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3083857A Pending CA3083857A1 (en) 2017-11-30 2018-11-30 Modified norovirus vp1 proteins and vlps comprising modified norovirus vp1 proteins

Country Status (15)

Country Link
US (2) US11602558B2 (enExample)
EP (1) EP3717648A4 (enExample)
JP (2) JP7579143B2 (enExample)
KR (1) KR102878449B1 (enExample)
CN (1) CN111727255A (enExample)
AU (1) AU2018375695B2 (enExample)
BR (1) BR112020010799A2 (enExample)
CA (1) CA3083857A1 (enExample)
IL (1) IL274736A (enExample)
MX (1) MX2020005530A (enExample)
PH (1) PH12020550732A1 (enExample)
RU (1) RU2020116307A (enExample)
SG (1) SG11202004668WA (enExample)
WO (1) WO2019104439A1 (enExample)
ZA (2) ZA202003831B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7420339B2 (ja) * 2019-10-11 2024-01-23 学校法人北里研究所 変異ノロウイルス粒子とその生産方法
US20230381293A1 (en) * 2020-10-14 2023-11-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic Stabilized norovirus virus-like particles as vaccine immunogens
CN113481328B (zh) * 2021-07-23 2023-10-27 中国科学院微生物研究所 用于检测临床样本中gi.5型诺如病毒的试剂盒及专用引物
JP2024540061A (ja) * 2021-10-27 2024-10-31 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア ノロウイルスワクチン及び使用法
CN118252924A (zh) * 2022-12-27 2024-06-28 远大赛威信生命科学(南京)有限公司 用于诱发哺乳动物针对诺如病毒的免疫反应的药物组合物及其制备方法和用途
WO2025077799A1 (en) * 2023-10-12 2025-04-17 Chengdu Kanghua Biological Products Co., Ltd. Method of preparing norovirus vaccine without adjuvant
WO2025076792A1 (en) * 2023-10-12 2025-04-17 Chengdu Kanghua Biological Product Co., Ltd. Methods of preparing norovirus vaccine with low amounts of adjuvant
CN118126202B (zh) * 2024-05-07 2024-07-30 上海瑞宙生物科技有限公司 一种诺如病毒类病毒颗粒及其应用
CN118773218B (zh) * 2024-08-22 2025-09-30 中国医学科学院医学生物学研究所 一种诺如病毒gii.17型病毒样颗粒及其制备方法与应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7879338B2 (en) 2003-07-21 2011-02-01 Boyce Thompson Institute For Plant Research Vectors and methods for immunization against norovirus using transgenic plants
AU2007303608B2 (en) 2006-09-29 2013-05-02 Takeda Vaccines, Inc. Norovirus vaccine formulations
JP5852883B2 (ja) 2008-08-08 2016-02-03 タケダ ワクチン，インコーポレイテッド 交差反応性の増強のための複合カプシドアミノ酸配列を含むウイルス様粒子
MX2012003372A (es) * 2009-09-22 2012-05-29 Medicago Inc Metodo para preparar proteina derivada de vegetales.
EP2591097A1 (en) 2010-07-06 2013-05-15 Novartis AG Norovirus derived immunogenic compositions and methods
EP2956169B1 (en) * 2013-02-12 2018-04-11 THE UNITED STATES OF AMERICA, represented by the S Monoclonal antibodies that neutralize norovirus
US9975923B2 (en) 2013-03-15 2018-05-22 The University Of North Carolina At Chapel Hill Methods and compositions for norovirus blockade epitopes
AR096236A1 (es) * 2013-05-09 2015-12-16 The Us Secretary Dept Of Health And Human Services Nat Inst Of Health Office Of Tech Transfer Anticuerpos de dominio simple vhh dirigidos a norovirus gi.1 y gii.4 y sus usos
JP5963811B2 (ja) 2014-07-18 2016-08-03 オリンパス株式会社 治療用超音波振動子
EP3037386A1 (en) 2014-12-23 2016-06-29 Casale SA A plant and a process for ammonia production with cryogenic purification, and a related method of revamping
EA201792512A1 (ru) * 2015-06-12 2018-06-29 Вэксарт, Инк. Составы для доставки антигенов респираторного синтициального вируса и норовируса в тонкий кишечник
EP3452493B1 (en) * 2016-05-04 2025-01-15 CureVac SE Nucleic acid molecules and uses thereof
WO2018170603A1 (en) * 2017-03-23 2018-09-27 Medicago Inc. Norovirus fusion proteins and vlps comprising norovirus fusion proteins

Also Published As

Publication number Publication date
CN111727255A (zh) 2020-09-29
US20230293663A1 (en) 2023-09-21
KR102878449B1 (ko) 2025-10-30
MX2020005530A (es) 2021-01-15
JP7579143B2 (ja) 2024-11-07
AU2018375695B2 (en) 2025-01-02
EP3717648A4 (en) 2021-12-01
AU2018375695A1 (en) 2020-06-11
IL274736A (en) 2020-07-30
US20200330583A1 (en) 2020-10-22
JP2021503962A (ja) 2021-02-15
US12076388B2 (en) 2024-09-03
JP2024109835A (ja) 2024-08-14
BR112020010799A2 (pt) 2020-11-10
EP3717648A1 (en) 2020-10-07
WO2019104439A1 (en) 2019-06-06
PH12020550732A1 (en) 2021-04-19
KR20200092363A (ko) 2020-08-03
ZA202003831B (en) 2023-10-25
SG11202004668WA (en) 2020-06-29
ZA202306500B (en) 2024-10-30
US11602558B2 (en) 2023-03-14
RU2020116307A (ru) 2021-12-30

Similar Documents

Publication Publication Date Title
US12076388B2 (en) Modified norovirus VP1 proteins and VLPS comprising modified norovirus VP1 proteins
US11987601B2 (en) Norovirus fusion proteins and VLPs comprising norovirus fusion proteins
KR20210025626A (ko) 인플루엔자 바이러스 헤마글루티닌 돌연변이들
US11759512B2 (en) Modified norovirus VP1 proteins and VLPs comprising modified norovirus VP1 proteins
TW202018084A (zh) 修飾之諾羅病毒vp1蛋白及包含修飾之諾羅病毒vp1蛋白之vlp
WO2023049983A1 (en) Cpmv vlps displaying sars-cov-2 epitopes
WO2024040325A1 (en) Modified influenza b virus hemagglutinin
MX2015002835A (es) Produccion de particulas similares a picornavirus en plantas.

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20231016